Dual FGFR-targeting and pH-activatable ruthenium–peptide conjugates for targeted therapy of breast cancer

Authors:

Abstract
We report a drug delivery system containing a cytotoxic ruthenium complex tethered to a FGFR-targeting peptide. The system showed controlled release of the active complex in breast cancer cells resulting in improved antiproliferative activity and selectivity.
Funding Information
  • Ministerio de Ciencia e Innovación (PID2020-112821GB-I00)
  • Fundação para a Ciência e a Tecnologia (2020/02383/CEECIND, 2022/00028/CEECIND, 2023.01155.BD, CEECIND/02300/2017, LA/P/0056/2020, PTDC/QUI-OUT/3854/2021, PTDC/QUI-QIN/0146/2020, SFRH/BD/135915/2018, UI/BD/154814/2023, UID/Multi/04349/2019, UIDB/00100/2020, UIDB/04046/2020, UIDP/04046/2020)

This publication has 78 references indexed in Scilit: